BMRN vs. NTRA: BioMarin Pharmaceutical vs. Natera Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and Natera (NTRA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and Natera (NTRA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BMRN | NTRA |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | Natera, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.85 billion USD | 45.05 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 26, 1999 | July 1, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | NTRA |
|---|---|---|
| Total Return (1Y) | 8.82% | 61.03% |
| Total Return (3Y, Annualized) | -12.54% | 92.02% |
| Total Return (5Y, Annualized) | -7.51% | 23.20% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Natera (NTRA) has an aggressive beta of 1.58, indicating higher sensitivity to broad-market moves, while BioMarin Pharmaceutical (BMRN) is defensive at 0.24 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | BMRN | NTRA |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 52.30% |
| Beta (5Y) | 0.24 | 1.58 |
| Max Drawdown (5Y) | -57.64% | -75.72% |
| Avg. Volume (3M) | 2.28M | 1.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | NTRA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | 1.09 |
| Sortino Ratio (1Y) | 0.23 | 1.63 |
Profitability
ROE (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.31% and Natera (NTRA) at -10.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.52% and Natera (NTRA) at -5.66% report negative net margin values, usually indicating net losses over the period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
Operating Margin (TTM)
Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioMarin Pharmaceutical (BMRN) reports 26.58%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BMRN | NTRA |
|---|---|---|
| ROE (TTM) | -0.31% | -10.55% |
| ROA (TTM) | 3.89% | -6.79% |
| Net Margin (TTM) | -0.52% | -5.66% |
| Operating Margin (TTM) | 26.58% | -7.64% |
| Gross Margin (TTM) | 53.21% | 65.14% |
Growth
Revenue Growth
Both BioMarin Pharmaceutical (BMRN) at 12.87% and Natera (NTRA) at 35.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.
Growth Metrics
| Metric | BMRN | NTRA |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | 35.90% |
| Revenue Growth (3Y CAGR) | 15.40% | 41.14% |
| EPS Growth (YoY) | -18.55% | -- |
| EPS Growth (3Y CAGR) | 33.89% | -- |
Financial Strength
Current Ratio (MRQ)
Natera (NTRA) at 2.81 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Natera (NTRA) at 0.13 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BMRN | NTRA |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | 2.81 |
| Debt / Equity (MRQ) | 0.67 | 0.13 |
| Net Debt / EBITDA | 4.04 | -- |
Dividends
Dividend Yield (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | NTRA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Natera (NTRA) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Natera (NTRA) at 15.49 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioMarin Pharmaceutical (BMRN) at 1.73 sits near its industry’s typical P/B ratio, while Natera (NTRA) at 23.99 prices above its benchmark range — NTRA looks rich relative to book.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BMRN | NTRA |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.97 | 15.49 |
| P/B Ratio (MRQ) | 1.73 | 23.99 |
| Free Cash Flow Yield (TTM) | -0.15% | 0.19% |